Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- Chemoradiation May Help Some Patients with Bladder Cancer Avoid Radical Surgery
(Posted: 05/14/2012) - Researchers in the United Kingdom have found that adding chemotherapy to radiation therapy as a treatment for bladder cancer may reduce the risk of a recurrence more than radiation alone, without causing a substantial increase in side effects.
- Drug for Multiple Myeloma Demonstrated to Significantly Extend Disease-Free Survival
(Posted: 12/18/2009, Updated: 05/09/2012) - Initial results from a large, randomized clinical trial for patients with multiple myeloma, a cancer of the blood and bone marrow, showed that patients who received the oral drug lenalidomide (Revlimid, also known as CC-5013) following a blood stem cell transplant had their cancer kept in check longer than patients who received a placebo.
- Combining Chemotherapy with Bevacizumab Improves Outcomes for Ovarian Cancer Patients
(Posted: 06/29/2011, Updated: 04/25/2012) - Results from two phase III randomized clinical trials suggest that, at least for some patients with ovarian cancer, adding the antiangiogenesis agent bevacizumab to chemotherapy increases the time to disease progression and may improve survival.
- Colonoscopy Reduces Risk of Death from Colorectal Cancer in High-Risk Patients
(Posted: 03/19/2012) - Long-term results from the National Polyp Study confirm that removing precancerous adenomas not only reduces the risk of colorectal cancer but also reduces the number of deaths from the disease by more than half. The findings appeared February 23, 2012, in the New England Journal of Medicine.
- Exemestane Reduces Breast Cancer Risk in High-Risk Postmenopausal Women
(Posted: 07/19/2011, Updated: 03/07/2012) - Clinical trial results presented at the 2011 ASCO annual meeting showed that the aromatase inhibitor exemestane (Aromasin®)—commonly used to treat early and advanced-stage breast cancer—substantially reduced the risk of invasive breast cancer in postmenopausal women at high risk of developing the disease.